News Prothena axes half its staff after phase 3 catastrophe Dublin biotech to focus on neurology drugs
News Novartis/Amgen's migraine drug hits market at lower than exp... The FDA has approved the first in a new class of migraine drugs, Novartis and Amgen’s Aimovig, and at a lower than expected list price of $6,900.
News FDA backs Novartis' Gilenya in paediatric MS First disease modifying therapy approved in paediatric MS
News e-Therapeutics and C4XD research Parkinson's drugs Biotechs search for new treatments for incurable disease
News FDA probes Parkinson's drug safety, Acadia's shares collapse FDA under pressure to act following press reports
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
